KRAS and non-small cell lung carcinoma: The recent development of KRAS-G12C inhibitors and their consequent FDA approval for non-small cell lung cancer shows the benefits and limitations of directly inhibiting RAS drivers (8, 9), and highlights the importance of targeting other members of the RAS family.